Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 1
2014 1
2016 2
2017 4
2018 1
2019 2
2020 6
2021 4
2022 11
2023 11
2024 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Author's reply.
Karimi M, Zargaran A, Alipour R. Karimi M, et al. Among authors: alipour r. J Acupunct Meridian Stud. 2022 Oct 31;15(5):279-280. doi: 10.51507/j.jams.2022.15.5.279. J Acupunct Meridian Stud. 2022. PMID: 36521825 No abstract available.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Epub 2023 Nov 30. Lancet Oncol. 2024. PMID: 38043558 Clinical Trial.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.
Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, Guminski A, Francis RJ, Saghebi J, Dhiantravan N, Joshua AM, Emmett L, Horvath L, Murphy DG, Hsiao E, Balakrishnar B, Lin P, Redfern A, Macdonald W, Ng S, Lee ST, Pattison DA, Nadebaum D, Kirkwood ID, Hofman MS; UpFrontPSMA Study Team. Azad AA, et al. Lancet Oncol. 2024 Oct;25(10):1267-1276. doi: 10.1016/S1470-2045(24)00440-6. Epub 2024 Sep 15. Lancet Oncol. 2024. PMID: 39293461 Clinical Trial.
Rescue effect of curcumin against copper toxicity.
Maghool F, Emami MH, Alipour R, Mohammadzadeh S, Sereshki N, Dehkordi SAE, Fahim A, Tayarani-Najaran Z, Sheikh A, Kesharwani P, Sahebkar A. Maghool F, et al. Among authors: alipour r. J Trace Elem Med Biol. 2023 Jul;78:127153. doi: 10.1016/j.jtemb.2023.127153. Epub 2023 Mar 14. J Trace Elem Med Biol. 2023. PMID: 36989586 Review.
PET/CT variants and pitfalls in malignant melanoma.
Aide N, Iravani A, Prigent K, Kottler D, Alipour R, Hicks RJ. Aide N, et al. Among authors: alipour r. Cancer Imaging. 2022 Jan 4;22(1):3. doi: 10.1186/s40644-021-00440-4. Cancer Imaging. 2022. PMID: 34983677 Free PMC article. Review.
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T.
Buteau JP, Kostos L, Alipour R, Jackson P, McInstosh L, Emmerson B, Haskali MB, Xie J, Medhurst E, Ravi R, Gonzalez BD, Fettke H, Blyth B, Furic L, Owen K, Sandhu S, Murphy DG, Azad AA, Hofman MS. Buteau JP, et al. Among authors: alipour r. J Nucl Med. 2024 Aug 1;65(8):1231-1238. doi: 10.2967/jnumed.124.267650. J Nucl Med. 2024. PMID: 38991752
Role of Melatonin in Body Weight: A Systematic Review and Meta-Analysis.
Mostafavi SA, Akhondzadeh S, Mohammadi MR, Keshtkar AA, Hosseini S, Eshraghian MR, Motlagh TA, Alipour R, Keshavarz SA. Mostafavi SA, et al. Among authors: alipour r. Curr Pharm Des. 2017;23(23):3445-3452. doi: 10.2174/1381612822666161129145618. Curr Pharm Des. 2017. PMID: 27897121 Review.
50 results